Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CSPC Pharmaceutical Group Limited (1093.HK)
Shijiazhuang, CN
CSPC Pharmaceutical Group Limited, primarily an investment holding entity, is dedicated to the development, production, and distribution of pharmaceutical goods. Its operations span the globe, with a significant presence in the People's Republic of China, across Asia, in the Americas, and throughout Europe. The company structures its business activities into three main divisions: Finished Drugs, Bulk Products, and Functional Food and Other ventures. The company's extensive portfolio of finished drugs encompasses treatments for a wide range of conditions. Key offerings include NBP (available as soft capsules and injections) for acute ischemic stroke, and Oulaining (capsules and injections) addressing mild to moderate memory and cognitive impairments. For neurological disorders, Enxi targets adult idiopathic Parkinson's disease. In oncology, Duomeisu treats lymphoma, multiple myeloma, ovarian and breast cancers, alongside other malignant tumors, while Jinyouli aids in preventing chemotherapy-induced leucopenia and infections, and Keaili is prescribed for breast cancer. Further therapeutic areas covered by CSPC include various infections, with products such as Shuluoke, Nuomoling, Weihong, and Xinweihong. Cardiovascular health is addressed by Xuanning for hypertension and Encun to avert atherosclerotic thrombosis events. Qixiao provides relief for upper respiratory tract infections, and diabetes management is supported by Linmeixin and Shuanglexin. Bone health solutions include Gubang and Gubangjia for postmenopausal osteoporosis. Additionally, Gaoshunsong offers relief for a broad spectrum of inflammatory and pain-related conditions, including arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursitis, tenosynovitis, acute gout, dysmenorrhea, toothache, postoperative pain, lower back pain, sprains, strains, and other soft tissue injuries. Other notable products include Debixin for various types of ulcers and Qimaite for acute and chronic pain management. Beyond finished pharmaceuticals, CSPC also supplies active pharmaceutical ingredients (APIs) like antibiotics, vitamin C, and caffeine. The company further diversifies into functional foods, glucose products, and provides healthcare services. Originally established in 1992, the company initially operated under the name China Pharmaceutical Group Limited before adopting its current designation, CSPC Pharmaceutical Group Limited, in March 2013. Its primary corporate office is situated in Shijiazhuang, within the People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.76% | -3.47% | -10.82% | -24.24% | -5.18% | -11.03% | -7.41% | +9.49% | -38.42% | +102.70% | +1,016.27% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 15 | -1 |
| Hold | 5 | 0 |
| Sell | 2 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%-14.2% Q4'25: -16.7% (vs Q4'23)
-
EPS growth Drug Manufacturers - General: +18.2%-12.1% Q4'25: -50.0% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+15.9% Q4'25: +15.9% (vs Q4'23)
-
EBIT margin Drug Manufacturers - General: +19.4%+15.3% Q4'25: +11.0% (vs Q4'23)
-
ROIC Drug Manufacturers - General: +10.2%+11.8% ★ Q4'25: +16.1% (vs Q4'23)
-
Share dilution Drug Manufacturers - General: +0.0%-2.7% ★ Q4'25: -2.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.12× ★ Q4'25: 0.08× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 12 Rev. Ana. 4 EPS Ana. |
Dec 2027 20 Rev. Ana. 11 EPS Ana. |
Dec 2028 15 Rev. Ana. 13 EPS Ana. |
Dec 2029 11 Rev. Ana. 11 EPS Ana. |
Dec 2030 7 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.97B
est: 5.34B (-63.1%)
|
3.34B
est: 3.62B (-7.7%)
|
7.93B
est: 5.92B (+33.9%)
|
8.63B
est: 7.02B (+23.0%)
|
9.53B
est: 9.84B (-3.2%)
|
11.08B
est: 11.14B (-0.5%)
|
13.04B
est: 12.55B (+3.9%)
|
18.45B
est: 17.60B (+4.8%)
|
22.08B
est: 22.73B (-2.9%)
|
23.58B
est: 25.95B (-9.1%)
|
27.41B
est: 27.97B (-2.0%)
|
31.59B
est: 31.08B (+1.7%)
|
31.47B
est: 29.44B (+6.9%)
|
29.54B
est: 29.47B (+0.2%)
|
25.33B
est: 27.84B (-9.0%)
|
32.44B
28.79B – 39.14B
+16.5% YoY
|
31.12B
24.19B – 40.80B
-4.1% YoY
|
33.39B
27.79B – 42.02B
+7.3% YoY
|
40.30B
33.55B – 50.73B
+20.7% YoY
|
44.82B
37.31B – 56.42B
+11.2% YoY
|
| EBITDA |
415.70M
est: 1.05B (-60.3%)
|
2.05B
est: 386.43M (+431.7%)
|
1.58B
est: 2.40B (-34.3%)
|
1.80B
est: 1.34B (+34.2%)
|
2.31B
est: 1.87B (+23.5%)
|
2.91B
est: 2.43B (+19.4%)
|
3.54B
est: 2.68B (+32.1%)
|
4.66B
est: 4.72B (-1.2%)
|
5.29B
est: 4.81B (+10.0%)
|
6.80B
est: 5.03B (+35.2%)
|
7.57B
est: 5.83B (+29.8%)
|
8.85B
est: 7.54B (+17.4%)
|
8.59B
est: 7.53B (+14.0%)
|
7.18B
est: 7.61B (-5.7%)
|
5.24B
est: 7.12B (-26.4%)
|
8.30B
7.36B – 10.01B
+16.5% YoY
|
7.96B
6.19B – 10.44B
-4.1% YoY
|
8.54B
7.11B – 10.75B
+7.3% YoY
|
10.31B
8.58B – 12.98B
+20.7% YoY
|
11.47B
9.54B – 14.43B
+11.2% YoY
|
| EBIT |
359.66M
est: 729.72M (-50.7%)
|
1.90B
est: 173.46M (+995.6%)
|
1.05B
est: 2.56B (-58.8%)
|
1.32B
est: 998.14M (+32.3%)
|
1.81B
est: 1.45B (+25.1%)
|
2.40B
est: 1.99B (+20.7%)
|
2.95B
est: 2.23B (+32.0%)
|
4.03B
est: 3.97B (+1.3%)
|
4.59B
est: 4.18B (+10.0%)
|
6.04B
est: 4.35B (+38.9%)
|
6.72B
est: 5.04B (+33.4%)
|
7.78B
est: 6.51B (+19.5%)
|
7.47B
est: 6.35B (+17.7%)
|
5.82B
est: 6.42B (-9.4%)
|
3.87B
est: 6.01B (-35.6%)
|
7.00B
6.21B – 8.44B
+16.5% YoY
|
6.71B
5.22B – 8.80B
-4.1% YoY
|
7.20B
6.00B – 9.07B
+7.3% YoY
|
8.69B
7.24B – 10.94B
+20.7% YoY
|
9.67B
8.05B – 12.17B
+11.2% YoY
|
| Net Income |
290.62M
est: 537.65M (-45.9%)
|
1.74B
est: 107.51M (+1,518.9%)
|
775.18M
est: 2.15B (-63.9%)
|
999.52M
est: 728.07M (+37.3%)
|
1.39B
est: 1.10B (+26.8%)
|
1.88B
est: 1.53B (+22.7%)
|
2.34B
est: 1.77B (+32.1%)
|
3.21B
est: 3.16B (+1.4%)
|
3.71B
est: 3.37B (+10.2%)
|
4.88B
est: 3.51B (+39.0%)
|
5.51B
est: 4.07B (+35.5%)
|
6.22B
est: 5.63B (+10.5%)
|
5.88B
est: 5.51B (+6.6%)
|
4.41B
est: 4.87B (-9.4%)
|
3.78B
est: 5.03B (-24.9%)
|
9.58B
4.46B – 12.66B
+90.4% YoY
|
4.95B
3.46B – 9.07B
-48.4% YoY
|
5.63B
3.79B – 11.84B
+13.9% YoY
|
9.59B
7.50B – 12.81B
+70.2% YoY
|
11.18B
8.75B – 14.95B
+16.6% YoY
|
| SGA |
483.40M
est: 820.02M (-41.0%)
|
799.07M
est: 517.05M (+54.5%)
|
1.53B
est: 984.68M (+55.5%)
|
1.84B
est: 1.44B (+28.2%)
|
2.34B
est: 2.03B (+15.7%)
|
2.99B
est: 2.58B (+16.0%)
|
4.23B
est: 2.82B (+50.4%)
|
7.16B
est: 5.77B (+24.0%)
|
9.45B
est: 7.48B (+26.4%)
|
9.80B
est: 8.94B (+9.5%)
|
11.27B
est: 10.36B (+8.8%)
|
11.72B
est: 13.40B (-12.5%)
|
10.35B
est: 10.17B (+1.8%)
|
9.93B
est: 10.28B (-3.4%)
|
7.09B
est: 9.62B (-26.3%)
|
11.21B
9.94B – 13.52B
+16.5% YoY
|
10.75B
8.36B – 14.10B
-4.1% YoY
|
11.53B
9.60B – 14.52B
+7.3% YoY
|
13.92B
11.59B – 17.52B
+20.7% YoY
|
15.48B
12.89B – 19.49B
+11.2% YoY
|
| EPS |
0.13
est: 0.15 (-13.7%)
|
0.62
est: 0.15 (+308.6%)
|
0.07
est: 0.10 (-25.0%)
|
0.09
est: 0.12 (-25.5%)
|
0.12
est: 0.12 (-1.0%)
|
0.16
est: 0.16 (+1.6%)
|
0.20
est: 0.20 (+1.4%)
|
0.27
est: 0.25 (+6.4%)
|
0.31
est: 0.32 (-4.3%)
|
0.41
est: 0.39 (+5.8%)
|
0.46
est: 0.47 (-1.5%)
|
0.52
est: 0.50 (+4.1%)
|
0.50
est: 0.47 (+6.4%)
|
0.38
est: 0.40 (-6.6%)
|
0.33
est: 0.44 (-24.6%)
|
0.68
0.39 – 1.11
+56.2% YoY
|
0.51
0.30 – 0.79
-24.7% YoY
|
0.58
0.33 – 1.04
+12.0% YoY
|
0.84
0.66 – 1.12
+45.6% YoY
|
0.98
0.77 – 1.31
+16.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-21 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-20 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-05 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-04 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-15 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dongchen Cai | Executive Chairman | 16M | male |
| Chunlei Li | Executive Director & Chief Scientist | 7M | male |
| Huaiyu Wang | Executive Director | 6M | male |
| Bing Yao | Executive Director | 6M | male |
| Cuilong Zhang | Executive Director | 6M | male |
| Weiping Chen | Executive Director | 6M | male |
| Xin Cai | Executive Director | 6M | male |
| Yiwei Zhang | Executive Director | 6M | male |
| Zhenguo Wang | Executive Director | 6M | male |
| Lei Cai | CEO & Vice Chairman of the Board | 592.3K | — |
| Qingjie Wei | COO & Vice-Chairman of the Board | 557.7K | male |
| Qingjei Wei | COO, Executive Director & Vice-Chairman of the Board | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1093.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
